Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (U.S. FDA) for Topiramate Capsules USP, 15 mg and 25 mg. Glenmark`s Topiramate Capsules USP, 15 mg and 25 mg has been determined by the FDA to be bioequivalent and therapeutically equivalent1 to Topamax�2 Capsules, 15 mg and 25 mg of Janssen Pharmaceuticals, Inc., and will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. According to IQVIATM sales data for the 12-month period ending May 2024, the Topamax� Capsules, 15 mg and 25 mg market achieved annual sales of approximately $21.9 million. Powered by Capital Market - Live News

Glenmark Specialty SA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC), determined by the FDA to be bioequivalent1 to Nexium�2 24 HR Delayed-Release Capsules, 20 mg (OTC), of Haleon U.S. Holdings LLC. Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics Inc., USA. According to Nielsen� syndicated data for the latest 52 weeks period ending 18 May 2024, the Nexium� 24 HR Delayed-Release Capsules, 20 mg (OTC) market achieved annual sales of approximately $259.2 million. Glenmark`s current portfolio consists of 197 products authorized for distribution in the U.S. marketplace and 50 ANDA`s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. Powered by Capital Market - Live News

Glenmark Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 24 May 2024, inter alia, have recommended the final dividend of Rs 2.5 per equity Share (i.e. 250%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net Loss of Glenmark Pharmaceuticals reported to Rs 1218.28 crore in the quarter ended March 2024 as against net loss of Rs 428.30 crore during the previous quarter ended March 2023. Sales rose 1.95% to Rs 3016.01 crore in the quarter ended March 2024 as against Rs 2958.37 crore during the previous quarter ended March 2023.For the full year,net loss reported to Rs 1501.67 crore in the year ended March 2024 as against net profit of Rs 297.25 crore during the previous year ended March 2023. Sales rose 1.78% to Rs 11635.46 crore in the year ended March 2024 as against Rs 11431.94 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales3016.012958.37 2 11635.4611431.94 2 OPM %16.7213.45 -10.2714.30 - PBDT1128.95246.35 358 1519.361574.87 -4 PBT977.61111.34 778 937.451005.69 -7 NP-1218.28-428.30 -184 -1501.67297.25 PL Powered by Capital Market - Live News

Glenmark Specialty S.A. (Glenmark), a subsidiary of Glenmark Pharmaceuticals announced an exclusive marketing and distribution agreement with BeiGene, a global oncology company. Under this agreement, Glenmark will register and commercialize BeiGene`s oncology medicines, Tislelizumab and Zanubrutinib in India. Tislelizumab is a novel anti-PD-1 monoclonal antibody approved by NMPA, EMA and FDA for the treatment of advanced or metastatic esophageal squamous cell carcinoma and broad development for the treatment of various types of cancers, and Zanubrutinib is a BTK inhibitor approved for the treatment of certain hematological malignancies, with results of several studies reinforcing its favorable efficacy and safety profile. Under this strategic collaboration, Glenmark will be responsible for locally required development, registration and distribution providing access to BeiGene`s innovative oncology medicines for cancer patients across India. Powered by Capital Market - Live News